User: Guest  Login
Title:

Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model.

Document type:
Journal Article; Research Support, Non-U.S. Gov't; Article
Author(s):
Borel, P; Benkhoucha, M; Weber, MS; Zamvil, SS; Santiago-Raber, ML; Lalive, PH
Abstract:
Glatiramer acetate (GA, copolymer-1, Copaxone), a therapy approved for treatment of multiple sclerosis (MS), prevents and reverses experimental autoimmune encephalomyelitis, the animal model of MS. In central nervous system autoimmune disease, GA is thought to act through modulation of antigen-presenting cells, such as monocytes, mediating an antigen-independent T(h)2 shift and development of FoxP3+ regulatory T cells. Recent reports indicate that GA may also be effective in models of other auto...     »
Journal title abbreviation:
Int Immunol
Year:
2008
Journal volume:
20
Journal issue:
10
Pages contribution:
1313-9
Language:
eng
Fulltext / DOI:
doi:10.1093/intimm/dxn086
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/18687587
Print-ISSN:
0953-8178
TUM Institution:
Neurologische Klinik und Poliklinik
 BibTeX